All articles by  

  1. Vaxart starts dosing in Phase Ib trial of norovirus vaccine

    Biotechnology firm Vaxart has commenced the dosing of patients in the randomised cohort of a Phase Ib clinical trial of…
    Read More…

    18 Apr
  2. Precision treats first patient in CAR T cell therapy trial

    Precision BioSciences has started treating patients in a Phase I/IIa clinical trial assessing its chimeric antigen receptor (CAR) T cell…
    Read More…

    18 Apr
  3. AveXis’ Zolgensma shows favourable profile in SMA Type 1

    Novartis unit AveXis has reported positive interim results from the ongoing Phase III STR1VE clinical trial of its gene therapy…
    Read More…

    18 Apr
  4. Cortexyme initiates new trial of Alzheimer’s medicine

    Pharmaceutical company Cortexyme has initiated a Phase II/III clinical trial to assess its investigational drug COR388 for the treatment of…
    Read More…

    17 Apr
  5. ProQR commences treatment in sepofarsen’s Phase II/III trial

    Dutch biotech firm ProQR Therapeutics has started dosing patients in a Phase II/III clinical trial of its investigational RNA-based oligonucleotide…
    Read More…

    17 Apr
  6. Emergent reports positive interim data for chikungunya vaccine

    Emergent BioSolutions has reported positive findings from the interim analysis of a Phase II clinical trial being conducted to assess…
    Read More…

    17 Apr
  7. Janssen’s diabetes drug Invokana reduces renal failure risk

    Janssen Pharmaceutical has reported Phase III CREDENCE trial results showing that its diabetes drug Invokana (canagliflozin) reduced the risk of…
    Read More…

    16 Apr
  8. Paradigm’s knee osteoarthritis study meets secondary endpoints

    Paradigm Biopharmaceuticals has announced that the Phase IIb clinical trial of injectable pentosan polysulfate sodium (iPPS) for treating osteoarthritis of…
    Read More…

    16 Apr
  9. Alnylam begins late-stage paediatric trial of lumasiran

    Alnylam Pharmaceuticals has launched a Phase III clinical trial of lumasiran to treat primary hyperoxaluria type 1 (PH1) in paediatric…
    Read More…

    16 Apr
  10. Gilead and Novo partner to trial combination therapy for NASH

    Gilead Sciences has entered a clinical collaboration with Denmark-based Novo Nordisk to evaluate a combination treatment for nonalcoholic steatohepatitis (NASH)….
    Read More…

    15 Apr

Go Top